In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 126 to 150 of 382

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Ex-situ machine perfusion devices for liver transplants	Health technology evaluation	TBC
Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests	Diagnostics guidance	TBC
Familial Breast Cancer: initial assessment and genetic testing (update)	NICE guideline	31 January 2027
Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]	Technology appraisal guidance	TBC
Fertility problems: assessment and treatment - update 1 and 2	NICE guideline	TBC
Fezolinetant for treating vasomotor symptoms associated with the menopause [ID5071]	Technology appraisal guidance	TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]	Technology appraisal guidance	TBC
Finerenone for treating heart failure with preserved or mildly reduced ejection fraction ID6514	Technology appraisal guidance	TBC
Flow tDCS	Medtech innovation briefings	TBC
Fordadistrogene movaparvovec for treating Duchenne muscular dystrophy [ID6133]	Technology appraisal guidance	TBC
Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]	Technology appraisal guidance	TBC
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]	Technology appraisal guidance	23 October 2025
GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain	Medical technologies guidance	TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312	Technology appraisal guidance	TBC
Givinostat for treating Duchenne muscular dystrophy in people 6 years and over [ID6323]	Technology appraisal guidance	18 September 2025
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma [ID6202]	Technology appraisal guidance	TBC
Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [ID6487]	Technology appraisal guidance	17 December 2025
Govorestat for treating classic galactosemia in people 2 to 65 years [TSID12071]	Technology appraisal guidance	TBC
Guselkumab for previously treated moderately to severely active Crohn's disease ID6238	Technology appraisal guidance	28 August 2025
Guselkumab for treating moderately to severely active ulcerative colitis [ID6237]	Technology appraisal guidance	28 August 2025
Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]	Technology appraisal guidance	22 April 2026
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]	Technology appraisal guidance	TBC
Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]	Technology appraisal guidance	TBC
Iclepertin for treating cognitive impairment associated with schizophrenia [ID6483]	Technology appraisal guidance	TBC
Idebenone for treating visual impairment in Leber's hereditary optic neuropathy in people 12 years and over [ID547]	Technology appraisal guidance	11 September 2025

Results per page

10
25
50
All